Clinical efficiency and tolerability of artrofoon in patients with rheumatoid arthritis associated with osteopenic syndrome.
Clinical, laboratory, densitometric, and prognostic parameters were evaluated in 50 patients with rheumatoid arthritis complicated with osteopenic syndrome, 30 of these received artofoon for 12 months in addition to basis therapy. Antiinflammatory and analgesic effects of artrofoon were demonstrated and the possibility of using this preparation in pharmacotherapy of rheumatoid arthritis associated with osteopenic syndrome was proven.
Peshekhonova
L K
LK
N N Burdenko Voronezh State Medical Academy, Federal Agency for Health Care and Social Development.
Chernov
Yu N
YN
Barsukova
N A
NA
Peshekhonov
D V
DV
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C503436:Artrofoon